CYP3A4 Inhibitors and Inducers
Strong CYP3A4 inhibitors and inducers cause clinically significant drug interactions that can lead to toxicity or therapeutic failure, and must be recognized to avoid dangerous combinations with CYP3A4 substrate medications.
Strong CYP3A4 Inhibitors
The following medications are consistently identified across multiple guidelines as strong CYP3A4 inhibitors 1:
Antifungals (Azoles)
- Ketoconazole - causes 2.5-fold increase in rivaroxaban exposure 2
- Itraconazole - contraindicated with many CYP3A4 substrates 1
- Voriconazole 1
- Posaconazole 2
HIV Protease Inhibitors
- Ritonavir - causes 2.5-fold increase in drug exposure 2
- Atazanavir 1
- Indinavir 1
- Nelfinavir 1
- Saquinavir 1
Macrolide Antibiotics
- Clarithromycin - causes 1.5-fold increase in rivaroxaban exposure 2
- Telithromycin 1
- Erythromycin - causes 1.3-fold increase in drug exposure 2
Other Strong Inhibitors
Strong CYP3A4 Inducers
The following medications are consistently identified as strong CYP3A4 inducers 1:
Anticonvulsants
- Phenytoin - causes 50% decrease in rivaroxaban exposure 2
- Carbamazepine 1
- Phenobarbital 1
- Oxcarbazepine 4
Antimycobacterials
Corticosteroids
- Dexamethasone (systemic) 1
Herbal Products
- St. John's Wort (Hypericum perforatum) - causes unpredictable decreases in drug levels 1
Clinical Implications
When Strong Inhibitors Are Combined with CYP3A4 Substrates:
- Drug exposure can increase 2.5 to 20-fold 2
- Risk of toxicity, bleeding (with anticoagulants), or QT prolongation
- Avoid the combination or interrupt the CYP3A4 substrate 1
- If unavoidable, reduce substrate dose and monitor closely
When Strong Inducers Are Combined with CYP3A4 Substrates:
- Drug exposure can decrease to 5-10% of original levels 2
- Risk of therapeutic failure, thromboembolism (with anticoagulants)
- Avoid the combination 1
- If unavoidable, increase substrate dose substantially and monitor for efficacy
Critical Pitfall:
Dual CYP3A4 and P-glycoprotein inhibitors (like azole antifungals and HIV protease inhibitors) cause the most profound interactions because they block both metabolism and efflux transport 2, 3. These combinations are typically contraindicated with narrow therapeutic index drugs like rivaroxaban, apixaban, and nilotinib.